NEW YORK, August 15 (Praxis Press). Animal studies and some cohort studies in humans have raised concerns about the carcinogenicity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase ...

A literature search was completed using MEDLINE (1966 February 7, 2004) and EMBASE (1980 December 2003) using the following search terms: C-reactive protein, statin or HMG-CoA reductase inhibitors ...

Genetic inhibition of HMG-CoA reductase, a state that mimics long-term statin use, was associated with greater risk for developing cataract compared with individuals without genetic inhibition ...

These patients were divided into two groups based on the use of HMG CoA reductase inhibitors. A total of 207 patients were identified of which, 60 were in statin group and 147 were in the non-statin ...

Background: 3-hydroxy-2-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors are effective lipid-lowering agents that also inhibit the growth of colon cancer cell lines and were noted to be ...

Some statins work best in the evening, while others work just as well in the morning. The best time to take statins depends ...

They act through inhibition of the enzyme HMG CoA reductase. Almost a fifth of them develop muscle symptoms (“statin myopathy”) including weakness and pain.

Rosuvastatin, especially at higher doses, was linked with hematuria and proteinuria when the HMG-CoA reductase inhibitor was first approved by the FDA in 2003, but post-marketing surveillance data ...

Cite this: HMG-CoA Reductase Inhibitors for Lowering Elevated Levels of C-Reactive Protein - Medscape - Aug 15, 2004.